• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Bio-Bridge Science, Inc. (BGES) - Financial and Strategic SWOT Analysis Review Product Image

Bio-Bridge Science, Inc. (BGES) - Financial and Strategic SWOT Analysis Review

  • ID: 1367852
  • August 2011
  • 38 pages
  • GlobalData

FEATURED COMPANIES

  • Aventis Pasteur Ltd.
  • BioClonetics Incorporated
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Oxford BioMedica plc
  • MORE

Bio-Bridge Science, Inc. (BGES) - Financial and Strategic SWOT Analysis Review

Summary

Bio-Bridge Science, Inc. (Bio-Bridge) is a development stage biotechnology company, engaged in the commercial development of biological products for the prevention and treatment of human infectious diseases, and production material in producing vaccines. It also provides bovine serum, which is a production material in producing vaccines. The company owns the license for the HIV vaccine and colon cancer vaccine technology to develop and sell it in the territories of the People's Republic of China, Japan, and the US. Currently, Bio-Bridge is involved in the development and commercialization of HIV-PV Vaccine I, used to prevent and treat infection by the human immunodeficiency virus (HIV). Bio-Bridge Science is headquartered in Illinois, the US.

Bio-Bridge Science, Inc. Key Recent Developments…

Nov 19, 2010 Bio-Bridge Science Reports Net Loss Of $0.5 Million For Q3 2010
Aug 16, 2010 Bio-Bridge Science Reports Net Loss Of $0.4 Million For Q2 2010
Jul 08, 2010 Bio-Bridge Science To Relocate Headquarters To Oakbrook Terrace, Illinois
May 17, 2010 Bio-Bridge READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aventis Pasteur Ltd.
  • BioClonetics Incorporated
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Oxford BioMedica plc
  • MORE



List of Tables
List of Figures
Section 1 - About the Company
Bio-Bridge Science, Inc. - Key Facts
Bio-Bridge Science, Inc. - Key Employees
Bio-Bridge Science, Inc. - Key Employee Biographies
Bio-Bridge Science, Inc. - Major Products and Services
Bio-Bridge Science, Inc. - Pharmaceutical Pipeline Products Data
Bio-Bridge Science, Inc., Pipeline Products by Therapy Area
Bio-Bridge Science, Inc., Pipeline Products by Development Phase
Bio-Bridge Science, Inc. - History
Bio-Bridge Science, Inc. - Company Statement
Bio-Bridge Science, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Bio-Bridge Science, Inc. - Business Description
Bio-Bridge Science, Inc. - SWOT Analysis
SWOT Analysis - Overview
Bio-Bridge Science, Inc. - Strengths
Strength - Strategic Relationships
Strength - Unique Technology
Strength - Productive Acquisitions
Weakness - Lack of Manufacturing Experience
Weakness - Limited Liquidity Position
Weakness - History of Losses
Opportunity - Emerging Markets
Opportunity - Market Potential of HIV/AIDS
Opportunity - Rising Healthcare Expenditure in the US
Threat - Competitive Marketplace
Threat - Tightening of FDA’s Regulatory Oversight
Threat - Uncertainties from Clinical R&D Activities
Bio-Bridge Science, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Bio-Bridge Science, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Bio-Bridge Science, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Bio-Bridge Science, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 19, 2010: Bio-Bridge Science Reports Net Loss Of $0.5 Million For Q3 2010
Aug 16, 2010: Bio-Bridge Science Reports Net Loss Of $0.4 Million For Q2 2010
Jul 08, 2010: Bio-Bridge Science To Relocate Headquarters To Oakbrook Terrace, Illinois
May 17, 2010: Bio-Bridge Science Reports Net Loss Of $1.9 Million For Q1 2010
Apr 12, 2010: Bio-Bridge Science Receives Papilloma Pseudovirus Technology Patent In Japan
Apr 12, 2010: Bio-Bridge Science Announces Receipt Of Papilloma Pseudovirus Technology Patent In Japan
Mar 31, 2010: Bio-Bridge Science Reports Net Loss Of $0.8 Million For 2009
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

Oxford BioMedica plc
Aventis Pasteur Ltd.
Novartis Vaccines and Diagnostics, Inc.
GlaxoSmithKline plc
Merck & Co., Inc.
BioClonetics Incorporated

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS